Cargando…

Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial

Background: Inflammation has a major role in disease lead to renal failure and diabetes mellitus, controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality. Objectives: This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Arashnia, Rana, Roohi-Gilani, Kobra, Karimi-Sari, Hamidreza, Nikjoo, Niloofar, Bahramifar, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Diabetic Nephropathy Prevention 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417670/
https://www.ncbi.nlm.nih.gov/pubmed/25964889
http://dx.doi.org/10.12860/jnp.2015.10
_version_ 1782369391760900096
author Arashnia, Rana
Roohi-Gilani, Kobra
Karimi-Sari, Hamidreza
Nikjoo, Niloofar
Bahramifar, Ali
author_facet Arashnia, Rana
Roohi-Gilani, Kobra
Karimi-Sari, Hamidreza
Nikjoo, Niloofar
Bahramifar, Ali
author_sort Arashnia, Rana
collection PubMed
description Background: Inflammation has a major role in disease lead to renal failure and diabetes mellitus, controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality. Objectives: This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid profile in diabetic kidney transplant receivers. Patients and Methods: In this double blinded clinical trial, 58 diabetic renal transplant receivers, in first month after transplantation, randomized into two groups; receiving insulin and pioglitazone (15 mg tablet daily, group A); and insulin and placebo (group B). Blood pressure, weight, body mass index (BMI) and laboratory data compared in before and after 4-month treatment in two groups by SPSS. Results: Fifty-eight patients with mean age of 44.15 ± 2 years included. There were no significant difference between groups in demographic data and other baseline measured variables (P > 0.05) .The mean weigh and BMI were slightly increased in group A and decreased in group B. The mean hs-CRP was decreased 4.82 mg/dL in group A and 1.93 mg/dL in group B (P = 0.007). The mean total serum cholesterol was significantly decreased 34 mg/dL in group A and 18.07 mg/dL in group B (P = 0.027). The mean serum HDL-C was significantly increased 13.31 mg/dL in group A and 5.89 mg/dl in group B (P < 0.001). Conclusions: Pioglitazone seems to be a safe drug for reducing serum lipids and CRP in kidney transplant receivers with diabetes mellitus in short term. Long term effect of this drug could be evaluated in future studies.
format Online
Article
Text
id pubmed-4417670
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Society of Diabetic Nephropathy Prevention
record_format MEDLINE/PubMed
spelling pubmed-44176702015-05-11 Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial Arashnia, Rana Roohi-Gilani, Kobra Karimi-Sari, Hamidreza Nikjoo, Niloofar Bahramifar, Ali J Nephropathol Original Article Background: Inflammation has a major role in disease lead to renal failure and diabetes mellitus, controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality. Objectives: This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid profile in diabetic kidney transplant receivers. Patients and Methods: In this double blinded clinical trial, 58 diabetic renal transplant receivers, in first month after transplantation, randomized into two groups; receiving insulin and pioglitazone (15 mg tablet daily, group A); and insulin and placebo (group B). Blood pressure, weight, body mass index (BMI) and laboratory data compared in before and after 4-month treatment in two groups by SPSS. Results: Fifty-eight patients with mean age of 44.15 ± 2 years included. There were no significant difference between groups in demographic data and other baseline measured variables (P > 0.05) .The mean weigh and BMI were slightly increased in group A and decreased in group B. The mean hs-CRP was decreased 4.82 mg/dL in group A and 1.93 mg/dL in group B (P = 0.007). The mean total serum cholesterol was significantly decreased 34 mg/dL in group A and 18.07 mg/dL in group B (P = 0.027). The mean serum HDL-C was significantly increased 13.31 mg/dL in group A and 5.89 mg/dl in group B (P < 0.001). Conclusions: Pioglitazone seems to be a safe drug for reducing serum lipids and CRP in kidney transplant receivers with diabetes mellitus in short term. Long term effect of this drug could be evaluated in future studies. Society of Diabetic Nephropathy Prevention 2015-04 2015-04-01 /pmc/articles/PMC4417670/ /pubmed/25964889 http://dx.doi.org/10.12860/jnp.2015.10 Text en © 2015 The Author(s) Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Arashnia, Rana
Roohi-Gilani, Kobra
Karimi-Sari, Hamidreza
Nikjoo, Niloofar
Bahramifar, Ali
Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title_full Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title_fullStr Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title_full_unstemmed Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title_short Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
title_sort effect of pioglitazone therapy on high sensitive c-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417670/
https://www.ncbi.nlm.nih.gov/pubmed/25964889
http://dx.doi.org/10.12860/jnp.2015.10
work_keys_str_mv AT arashniarana effectofpioglitazonetherapyonhighsensitivecreactiveproteinandlipidprofileindiabeticpatientswithrenaltransplantationarandomizeclinicaltrial
AT roohigilanikobra effectofpioglitazonetherapyonhighsensitivecreactiveproteinandlipidprofileindiabeticpatientswithrenaltransplantationarandomizeclinicaltrial
AT karimisarihamidreza effectofpioglitazonetherapyonhighsensitivecreactiveproteinandlipidprofileindiabeticpatientswithrenaltransplantationarandomizeclinicaltrial
AT nikjooniloofar effectofpioglitazonetherapyonhighsensitivecreactiveproteinandlipidprofileindiabeticpatientswithrenaltransplantationarandomizeclinicaltrial
AT bahramifarali effectofpioglitazonetherapyonhighsensitivecreactiveproteinandlipidprofileindiabeticpatientswithrenaltransplantationarandomizeclinicaltrial